Discontinue use if serious allergic/hypersensitivity reactions including SJS occur. Not recommended in patients w/ ischaemic heart disease or CHF; patients in whom rate of urate formation is greatly increased eg, malignant disease & its treatment, Lesch-Nyhan syndrome; organ transplant recipients; rare hereditary problems of galactose intolerance. Not to be started until an acute attack of gout has completely subsided. Flare prophylaxis w/ NSAID or colchicine at treatment initiation for at least 6 mth is recommended. Patients w/ alteration of thyroid function. LFT is recommended prior to initiation of therapy & periodically thereafter. Not recommended in concomitant use w/ mercaptopurine/azathioprine. Exercise caution before driving, using machinery or participating in dangerous activities. Efficacy & safety have not been fully evaluated in patients w/ severe renal impairment (CrCl <30 mL/min) & not been studied in patients w/ severe hepatic impairment (Child-Pugh class C). Limited information in patients w/ moderate hepatic impairment. Not to be used during pregnancy & lactation. Safety & efficacy have not been established in childn <18 yr.
Sign Out
